Microbial β-glucuronidase is associated with variations in clozapine serum levels in patients with treatment-resistant schizophrenia

Background: Clozapine is the most effective treatment for people with treatment-resistant schizophrenia (TRS). However, clozapine blood levels vary up to 15-fold across patients, and known determinants (cytochrome P450 modulation, smoking, demographics) explain only part of this variability. Identifying additional factors could help lower toxicity risk, reduce reliance on intensive therapeutic drug monitoring, and widen access to an effective treatment. We evaluated whether gut microbial β-glucuronidase was associated with clozapine serum concentration-to-dose (C/D) ratio, hypothesising that intestinal bacterial deconjugation of N-glucuronidated clozapine enables its re-absorption through the enterohepatic circulation. Methods: We conducted a secondary analysis of a cross-sectional cohort of adults with TRS on stable clozapine treatment who provided paired blood and stool samples ( N = 46). Shotgun metagenomic data were processed to quantify microbial β-glucuronidase (KEGG ortholog K01195). Ordinary least squares regression tested the association between β-glucuronidase abundance and clozapine C/D ratio, unadjusted and adjusted for sex, smoking, ethnicity, stool type, constipation, diet, body mass index, age, total antipsychotic dose, and blood-to-stool sample interval. Results: Microbial β-glucuronidase was positively associated with clozapine C/D ratio in the unadjusted model (β = 0.145, 95% CI [0.001, 0.288]; p = 0.048, adjusted R 2 = 0.07). This association strengthened after adjustment (β = 0.236, 95% CI [0.084, 0.388], p = 0.004, adjusted R 2 = 0.25, full covariate model), corresponding to a 26.65% higher C/D ratio per unit increase. β-glucuronidase was not associated with gastrointestinal symptoms (p = 0.235, unadjusted). Conclusions: These findings provide the first evidence that a specific gut microbial enzyme can modulate clozapine exposure in patients. If confirmed in independent cohorts, these findings can pave the way for microbiome-based precision dosing in psychiatry.

Authors

Institutions

Publication Details

Journal
Journal of Psychopharmacology
Published
2026-11-19
DOI
https://doi.org/10.1177/02698811261504421
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Microbial β-glucuronidase is associated with variations in clozapine serum levels in patients with treatment-resistant schizophrenia

Dan J. Siskind, Philip McGuire, Svetlina S. Vasileva, Philip W. J. Burnet et al.
Journal of Psychopharmacology
Pharmacogenetics and Drug Metabolism
article

Microbial β-glucuronidase is associated with variations in clozapine serum levels in patients with treatment-resistant schizophrenia

Dan J. Siskind, Philip McGuire, Svetlina S. Vasileva, Philip W. J. Burnet, Darryl Walter Eyles, Jacob Gratten, Belinda Lennox, Amedeo Minichino, Robert Ali McCutcheon, Andrea Baker
article en

Abstract

Background: Clozapine is the most effective treatment for people with treatment-resistant schizophrenia (TRS). However, clozapine blood levels vary up to 15-fold across patients, and known determinants (cytochrome P450 modulation, smoking, demographics) explain only part of this variability. Identifying additional factors could help lower toxicity risk, reduce reliance on intensive therapeutic drug monitoring, and widen access to an effective treatment. We evaluated whether gut microbial β-glucuronidase was associated with clozapine serum concentration-to-dose (C/D) ratio, hypothesising that intestinal bacterial deconjugation of N-glucuronidated clozapine enables its re-absorption through the enterohepatic circulation. Methods: We conducted a secondary analysis of a cross-sectional cohort of adults with TRS on stable clozapine treatment who provided paired blood and stool samples ( N = 46). Shotgun metagenomic data were processed to quantify microbial β-glucuronidase (KEGG ortholog K01195). Ordinary least squares regression tested the association between β-glucuronidase abundance and clozapine C/D ratio, unadjusted and adjusted for sex, smoking, ethnicity, stool type, constipation, diet, body mass index, age, total antipsychotic dose, and blood-to-stool sample interval. Results: Microbial β-glucuronidase was positively associated with clozapine C/D ratio in the unadjusted model (β = 0.145, 95% CI [0.001, 0.288]; p = 0.048, adjusted R 2 = 0.07). This association strengthened after adjustment (β = 0.236, 95% CI [0.084, 0.388], p = 0.004, adjusted R 2 = 0.25, full covariate model), corresponding to a 26.65% higher C/D ratio per unit increase. β-glucuronidase was not associated with gastrointestinal symptoms (p = 0.235, unadjusted). Conclusions: These findings provide the first evidence that a specific gut microbial enzyme can modulate clozapine exposure in patients. If confirmed in independent cohorts, these findings can pave the way for microbiome-based precision dosing in psychiatry.

Journal of Psychopharmacology
The University of Queensland (AU), Princess Alexandra Hospital (AU), Oxford Health NHS Foundation Trust (GB), National Institute for Health and Care Research (GB), University of Oxford (GB), Metro South Health (AU), Mater Research (AU), Queensland Centre for Mental Health Research (AU), Addiction and Mental Health Services - MSH (AU)
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon